Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2015. The document serves as a notification of transactions involving Persons Discharging Managerial Responsibilities (PDMR) under the GSK Deferred Annual Bonus Plan, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the fair market value of an Ordinary Share at the point of exercise on May 11, 2015, which was £14.73.
Material Changes
The filing details the exercise of nil-priced options by four PDMRs on May 11, 2015, for shares that vested on March 9, 2015. The net-of-tax shares delivered to each individual were as follows:
- Emma Walmsley: 7,478 shares
- Peter Vallance: 14,983 shares
- Colin Thomas: 10,819 shares
- Derek Redfern: 8,809 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a regulatory disclosure of director share transactions in accordance with the Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares issued to PDMRs under the Deferred Annual Bonus Plan.
- Confirm the share price of £14.73 used for valuation on May 11, 2015.
- Review the vesting schedule for options granted on March 9, 2012, to understand future dilution or compensation costs.
- Note that this filing does not contain operational or financial performance data for the period.